Issue Briefs

Online Simulation Model to Estimate the Total Costs of Tobacco Product Waste in Large U.S. Cities
Online Simulation Model to Estimate the Total Costs of Tobacco Product Waste in Large U.S. Cities 860 484 Avalon Health Economics LLC

Tobacco product waste (TPW) is one of the most ubiquitous forms of litter, accumulating in large amounts on streets, highways, sidewalks, beaches, parks, and other public places, and flowing into storm water drains, waste treatment plants, and solid waste collection facilities.

read more

Telehealth and Telemedicine in the Post-Pandemic Era
Telehealth and Telemedicine in the Post-Pandemic Era 860 484 Avalon Health Economics LLC

In many ways the arrival of the COVID-19 pandemic globally was met with sub-optimal levels of preparedness on the part of health care providers and provider systems, such as integrated delivery networks (IDNs).

read more

Moving Beyond ‘Lives-Saved’ From COVID-19
Moving Beyond ‘Lives-Saved’ From COVID-19 860 484 Avalon Health Economics LLC

This blog covers the presentation given as part of the ISPOR pre-conference plenary session on HEOR in the era of COVID-19 which was held on 14 May 2020.

read more

Economic Cycles and Product Development in Life Sciences
Economic Cycles and Product Development in Life Sciences 860 484 Avalon Health Economics LLC

The humanistic and economic consequences of the 2020 COVID-19 pandemic will not be completely understood for years. The humanistic toll has been well documented; as of early May 2020, the global death toll attributable to COVID-19 is more than 280,000, with more than 4 million confirmed cases.[1] Both numbers are believed to be substantial undercounts…

read more

Avalon’s Andrew Briggs Conducted Work on the Excess Mortality Attributable to COVID-19 Featured in the Wall Street Journal
Avalon’s Andrew Briggs Conducted Work on the Excess Mortality Attributable to COVID-19 Featured in the Wall Street Journal 860 484 Avalon Health Economics LLC

The Wall Street Journal recently covered the work that Avalon’s Andrew Briggs conducted on the excess mortality attributable to COVID-19. Briggs put the U.S. average at almost 14 years lost and the U.K. average at almost 11 years.

read more

Cost Impact Model of a Novel Multi-mRNA Host Response Assay for Diagnosis and Risk Assessment of Acute Respiratory Tract Infections and Sepsis in the Emergency Department
Cost Impact Model of a Novel Multi-mRNA Host Response Assay for Diagnosis and Risk Assessment of Acute Respiratory Tract Infections and Sepsis in the Emergency Department 860 484 Avalon Health Economics LLC

The Avalon team helped Inflammatix, Inc., develop economic evidence for HostDx Sepsis test for the diagnosis of acute infections. A newly released publication describes a cost impact model comparing the cost of standard of care versus the use of HostDx Sepsis in two hypothetical arms with 1000 patients presenting with symptoms of ARTI in the…

read more

Electronic Medical Records: Potential Issues in Litigation and Biomedical Research
Electronic Medical Records: Potential Issues in Litigation and Biomedical Research 860 484 Avalon Health Economics LLC

In this blog entry we explore some of the potentially important issues surrounding the role of EMRs in litigation, where the discovery of medical documents and records increasing involves digitally stored data.[1-4]

read more

Estimating QALY Losses Associated With Deaths in Hospital (COVID-19)
Estimating QALY Losses Associated With Deaths in Hospital (COVID-19) 860 484 Avalon Health Economics LLC

Avalon Director Andrew Briggs, DPhil, addresses the issue of potential losses in quality-adjusted life years (QALYs) associated with COVID-19.

read more

Applications of HEOR Analytics: Covariate-Adjusted Analysis of Phase 3 Clinical Trial Data of Lenvatinib versus Sorafenib in Hepatocellular Carcinoma
Applications of HEOR Analytics: Covariate-Adjusted Analysis of Phase 3 Clinical Trial Data of Lenvatinib versus Sorafenib in Hepatocellular Carcinoma 860 484 Avalon Health Economics LLC

In this blog entry we report on a good example of HEOR analytics: our recent study of covariate-adjusted analysis of trial data of lenvatinib versus sorafenib in hepatocellular carcinoma.

read more

COVID-19: Update on Epidemiology & Costs
COVID-19: Update on Epidemiology & Costs 860 484 Avalon Health Economics LLC

We define epidemiology broadly, including an up-to-date review of the key published medical literature on COVID-19. Following that, our discussion of costs focuses in part on the direct medical costs (which probably for good reasons has been relatively under-reported) and in part on the broader costs to the economy.

read more
Start Typing
Loading...